NASDAQ:TRAW Traws Pharma Q1 2025 Earnings Results & Report $0.28 +0.03 (+13.92%) Closing price 11/12/2026 03:59 PM EasternExtended Trading$0.28 -0.01 (-2.74%) As of 11/12/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Traws Pharma beat analyst earnings expectations and met on revenue in its Q1 2025 results, released May 15, 2025. The company reported EPS of $2.09 versus the -$8.04 consensus estimate, while revenue of $60 thousand matched the $60 thousand estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2025Report DateMay 15, 2025TimeBefore Market OpensConference Call7:00 AM ET Traws Pharma EPS ResultsActual EPS$2.09Consensus EPS -$8.04Beat/MissBeat by +$10.13One Year Ago EPSN/AEPS Beat Rate7 of last 8 quartersTraws Pharma Revenue ResultsActual Revenue$60 thousandExpected Revenue$60 thousandBeat/MissMet ExpectationsYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Traws Pharma Q1 2025 Earnings FAQ Did Traws Pharma beat earnings estimates for Q1 2025? Traws Pharma (NASDAQ:TRAW) reported earnings of $2.09 per share for Q1 2025, beating the consensus estimate of -$8.04. The report was announced on Thursday, May 15, 2025. What was Traws Pharma's revenue for Q1 2025? Traws Pharma reported revenue of $60 thousand for Q1 2025, against a consensus estimate of $60 thousand. Traws Pharma Earnings HeadlinesTraws Pharma Reports Final Phase 2a Results for Ratutrelvir in COVID-infected Subjects, Showing Fewer Treatment-Related Adverse Events and No Viral Rebounds Versus PAXLOVID®November 12 at 7:00 AM | globenewswire.comTraws Pharma (TRAW) vs. Its Competitors Financial AnalysisNovember 11 at 2:48 AM | americanbankingnews.comMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community before the big move happened. Now, I'm making my next big call. It's a coin under $1.00 that most investors have never heard of. But the world's largest bank is already building on it. It has a deflationary burn mechanism tied directly to institutional usage. With Bitcoin well off its highs and fear still hanging over the market, this is the exact environment where my biggest winners have been found. | Crypto 101 Media (Ad)Traws Pharma Updates Ratutrelvir COVID-19 Trial as Investors Await ResultsNovember 6, 2026 | tipranks.comTraws Pharma (TRAW) Expected to Post Earnings on ThursdayNovember 5, 2026 | americanbankingnews.comTraws Pharma, Inc. enters $50,000,000 common stock purchase agreement with Roth Principal InvestmentsOctober 23, 2026 | msn.comSee More Traws Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Traws Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Traws Pharma and other key companies, straight to your email. Email Address About Traws PharmaTraws Pharma (NASDAQ:TRAW) is a clinical-stage biotechnology company focused on developing antiviral medicines for respiratory viral infections, including influenza and COVID-19. The company’s approach includes developing therapies designed to act against viral replication and host-cell pathways involved in disease progression. Traws Pharma’s pipeline includes zapnometinib, an investigational oral host-directed antiviral designed to inhibit the MEK signaling pathway, which may support treatment across multiple strains of influenza and coronaviruses. The company is also developing additional antiviral candidates, including tivoxavir marboxil, an investigational treatment intended to target influenza virus replication. These products remain under clinical development and have not been approved for commercial use. The company was formed through the combination of Onconova Therapeutics, Inc. and Traws Pharma, LLC and adopted the Traws Pharma name in 2024. Its shares trade on the Nasdaq Capital Market under the symbol “TRAW.” Traws Pharma is headquartered in the United States and is focused on advancing its antiviral programs through clinical development and potential regulatory approval.View Traws Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping3 Pharmaceutical Stocks That Offer Safety and GrowthKeeping AI Cool: AAON Rides the AI Heatwave to Record GrowthPalantir’s Real Washington Risk Isn’t the Budget—It’s OversightCoreWeave's Backlog Is Surging—Can the Stock Follow?Can Constellation Energy's Contracts Power a Stock Rebound? Upcoming Earnings Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
